Eric Deutsch

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint Environmental, genetic, and molecular features of prostate cancer
    Eric Deutsch
    Laboratoire UPRES EA 27 10, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 5:303-13. 2004
  2. pmc Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation
    E Deutsch
    Laboratoire UPRES EA No 27 10, Radiosensibilite des tumeurs et tissus sains, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Br J Cancer 91:1735-41. 2004
  3. ncbi request reprint The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe
    Yungan Tao
    UPRES EA27 10 Laboratoire Radiosensibilité des Tumeurs et Tissus Sains, Villejuif, France
    Cell Cycle 8:3172-81. 2009
  4. doi request reprint [Cell cycle, mitosis and therapeutic applications]
    Antonin Levy
    Institut Gustave Roussy, Service de radiothérapie oncologie, Universite Paris XI, Villejuif, France
    Bull Cancer 98:1037-45. 2011
  5. ncbi request reprint Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response
    Yohann Loriot
    UPRES 27 10, Institut Gustave Roussy, Villejuif, France
    Anticancer Res 30:3869-78. 2010
  6. doi request reprint Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination
    Pierre Mordant
    UPRES 2710, Universite Paris XI, Institut Gustave Roussy, Villejuif, 94805 France
    Mol Cancer Ther 9:358-68. 2010
  7. doi request reprint Minimal residual disease in solid neoplasia: New frontier or red-herring?
    Pierre Mordant
    Institut Gustave Roussy, Universite Paris, Villejuif, France
    Cancer Treat Rev 38:101-10. 2012
  8. ncbi request reprint Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion
    Alexandre Kaliski
    Unité Propre de Recherche de l Enseignement Supérieur Equipe d Accueil 27 10, Villejuif, France
    Mol Cancer Ther 4:1717-28. 2005
  9. doi request reprint Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents
    Nicolas Magne
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
    Cancer Metastasis Rev 27:737-50. 2008
  10. doi request reprint The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials
    Nicolas Magne
    Department of Radiotherapy, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94 805 Villejuif, France
    Eur J Cancer 44:2133-43. 2008

Detail Information

Publications53

  1. ncbi request reprint Environmental, genetic, and molecular features of prostate cancer
    Eric Deutsch
    Laboratoire UPRES EA 27 10, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 5:303-13. 2004
    ..This transition also signals a substantial worsening of prognosis. Here, we review the most important findings in prostate carcinogenesis and the molecular anomalies associated with the androgen-refractory stage...
  2. pmc Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation
    E Deutsch
    Laboratoire UPRES EA No 27 10, Radiosensibilite des tumeurs et tissus sains, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Br J Cancer 91:1735-41. 2004
    ..Therefore, these data suggest that Tyrphostin AG1024 could represent the basis of a novel therapy for STI571 refractory CML...
  3. ncbi request reprint The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe
    Yungan Tao
    UPRES EA27 10 Laboratoire Radiosensibilité des Tumeurs et Tissus Sains, Villejuif, France
    Cell Cycle 8:3172-81. 2009
    ..Altogether, these data support the contention that AZD1152 mediates radiosensitization in vivo by enhancing mitotic catastrophe, which can be used as a biomarker of treatment efficacy...
  4. doi request reprint [Cell cycle, mitosis and therapeutic applications]
    Antonin Levy
    Institut Gustave Roussy, Service de radiothérapie oncologie, Universite Paris XI, Villejuif, France
    Bull Cancer 98:1037-45. 2011
    ..Promising preliminary data render these proteins potential targets for therapeutic development against cancer...
  5. ncbi request reprint Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response
    Yohann Loriot
    UPRES 27 10, Institut Gustave Roussy, Villejuif, France
    Anticancer Res 30:3869-78. 2010
    ..The present study evaluated the efficacy of combining BCL-2 ODN and radiation in small-cell lung cancers (SCLC) cell lines...
  6. doi request reprint Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination
    Pierre Mordant
    UPRES 2710, Universite Paris XI, Institut Gustave Roussy, Villejuif, 94805 France
    Mol Cancer Ther 9:358-68. 2010
    ..The combination of RAF and mTOR inhibitors is effective for enhancing antitumoral effects in cells with deregulation of both RAS-RAF and PI3K, possibly through the cross-inhibition of 4E binding protein 1 and S6 protein...
  7. doi request reprint Minimal residual disease in solid neoplasia: New frontier or red-herring?
    Pierre Mordant
    Institut Gustave Roussy, Universite Paris, Villejuif, France
    Cancer Treat Rev 38:101-10. 2012
    ....
  8. ncbi request reprint Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion
    Alexandre Kaliski
    Unité Propre de Recherche de l Enseignement Supérieur Equipe d Accueil 27 10, Villejuif, France
    Mol Cancer Ther 4:1717-28. 2005
    ..This model could provide in vivo evidence of the antitumor efficacy of combining a MMP inhibitor with ionizing radiation to target radiation-induced invasion and angiogenesis...
  9. doi request reprint Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents
    Nicolas Magne
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
    Cancer Metastasis Rev 27:737-50. 2008
    ....
  10. doi request reprint The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials
    Nicolas Magne
    Department of Radiotherapy, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94 805 Villejuif, France
    Eur J Cancer 44:2133-43. 2008
    ..Here we report all the different published clinical trials focusing on efficacy and toxicity in order to clarify and to summarise the present state-of-the-art of this particularly promising combination in solid tumour management...
  11. doi request reprint Targeted therapy-induced radiation recall
    Antonin Levy
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 49:1662-8. 2013
    ..A diverse range of chemotherapies has been associated with RR but no case series with targeted therapies (TT) has been reported...
  12. doi request reprint Stem cell tracking: toward clinical application in oncology?
    Monica Mangoni
    UPRES EA 2710, Gustave Roussy Institute, Villejuif, France
    Tumori 98:535-42. 2012
    ..Transfer of these preclinical cellular imaging modalities to stem cells has already been reported, and transfer to clinical practice within the next years can be reasonably considered...
  13. pmc Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells
    Pierre Mordant
    INSERM U1030 and Université Paris XI, Institut Gustave Roussy, Villejuif, France
    PLoS ONE 6:e26073. 2011
    ..We sought to compare and refine bioluminescent orthotopic mouse models of human localized NSCLC...
  14. doi request reprint Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy
    Céline Clémenson
    INSERM U1030, Radiothérapie moléculaire, Institut Gustave Roussy, Universite Paris XI, Villejuif, France
    Invest New Drugs 30:2173-86. 2012
    ..This provides a good rationale to further assess EHT 6706 in combination protocols and confirm these effects in vivo...
  15. ncbi request reprint Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints
    Yungan Tao
    UPRES EA27 10 Laboratoire Radiosensibilité des Tumeurs et Tissus Sains, University Paris Sud XI Kremlin Bicêtre and Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif, France
    Cell Cycle 8:1196-205. 2009
    ..Altogether these results suggest that Chir-124-mediated radiosensitization is profoundly influenced by the p53 and cell cycle checkpoint system...
  16. doi request reprint Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy
    Yohann Loriot
    Institute Gustave Roussy, Villejuif, France
    Nat Clin Pract Oncol 5:268-78. 2008
    ..We review the incidence and clinical patterns of the gastrointestinal and hepatic toxic effects induced by the main molecular-targeted therapies and propose some hypotheses for the causes of each adverse event...
  17. doi request reprint Oncologic and functional results after abdominoperineal resection plus pseudocontinent perineal colostomy for epidermoid carcinoma of the anus
    Diane Goere
    Department of Surgical Oncology, Institut Gustave Roussy, Cancer Center, Villejuif, France
    Dis Colon Rectum 52:958-63. 2009
    ....
  18. doi request reprint Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts
    Cyrus Chargari
    Radiothérapie moléculaire, Universite Paris XI, Institut Gustave Roussy, Villejuif, France
    Cancer Lett 312:209-18. 2011
    ..Further investigations are warranted with regard to the molecular mechanisms underlying its actions and its dependency regarding p53 status...
  19. doi request reprint Are RAS mutations predictive markers of resistance to standard chemotherapy?
    Yohann Loriot
    SITEP, Department of Medicine, University Paris XI, Institut Gustave Roussy, Villejuif, France
    Nat Rev Clin Oncol 6:528-34. 2009
    ..Therefore, KRAS mutations should not be used as molecular predictors of response to conventional chemotherapy...
  20. ncbi request reprint Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells
    Bixiu Wen
    UPRES EA No 27 10, Radiosensibilité des tumeurs et des tissues sains, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Urol 170:2036-9. 2003
    ..We examined the potential therapeutic effect of NS398, a selective cyclooxygenase-2 (COX-2) inhibitor, combined with irradiation on human prostate adenocarcinoma DU145 cells...
  21. doi request reprint Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trials
    Antonin Levy
    SITEP Service des Innovations Thérapeutiques Précoces, Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France
    Onkologie 36:357-62. 2013
    ..To analyze the clinical features and outcomes of advanced non-small cell lung cancer (NSCLC) patients treated in phase I trials...
  22. doi request reprint Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome
    Gabriel G Malouf
    Department of Radiotherapy, Institut de Cancerologie Gustave Roussy, Villejuif, France
    Eur J Cancer 49:1324-34. 2013
    ..Esthesioneuroblastomas, also called olfactory neuroblastomas (ENB) represent a rare sinonasal neurectodermal tumour which prognostic factors are unsteadily described...
  23. ncbi request reprint Sensitivity to radiation and alkylating agent of peripheral lymphocytes and fibroblasts in a Hoyeraal-Hreidarsson syndrome patient
    Radhia M'kacher
    Service de Pediatrie, Centre Hospitalier Universitaire de Besancon, Bescancon, France
    Pediatr Hematol Oncol 20:651-6. 2003
    ..The data suggest that conditioning regimens including TBI should not be used when a bone marrow transplantation procedure is planned in these patients...
  24. pmc Lung cancer stem cell: new insights on experimental models and preclinical data
    Caroline Rivera
    Laboratoire UPRES EA 27 10 Radiosensibilité des Tumeurs et Tissus Sains, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France
    J Oncol 2011:549181. 2011
    ..Preclinical data on putative CSC targets are emerging by now. These preliminary studies are critical for the next generation of lung cancer therapies...
  25. doi request reprint Unravelling the biology of human papillomavirus (HPV) related tumours to enhance their radiosensitivity
    Marie Catherine Vozenin
    UPRES EA 27 10 Radiosensibilité des tumeurs et tissus sains, Institut Gustave Roussy, Villejuif, France
    Cancer Treat Rev 36:629-36. 2010
    ....
  26. doi request reprint [Anti-apoptotic mechanisms in small-cell lung carcinoma]
    Yohann Loriot
    Departement de Medecine, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif, France
    Ann Pathol 30:17-24. 2010
    ..New therapies targeting some of these abnormalities are under clinical evaluation and predictive factors of response are needed to personalize these therapies...
  27. pmc Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells
    Abdessamad Amine
    Laboratoire UPRES EA 27 10 Radiosensibilité des Tumeurs et Tissus Sains, Institut Gustave Roussy Institut de Radioprotection et de Sureté Nucléaire, Villejuif, France
    PLoS ONE 4:e5018. 2009
    ..These data suggest a novel and highly translatable therapeutic approach to cervix cancer, by inhibition of adhesion and invasion of circulating HPV-positive tumor cells, using Cidofovir and/or ROCK inhibition...
  28. doi request reprint Concomitant chemo-radiotherapy in clinical trials: to promote step by step rational development
    Nicolas Magne
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Crit Rev Oncol Hematol 70:206-15. 2009
    ..A caveat is directed at radiation oncologists, at the expense of scientific reliability and validity which surely, should not be compromised...
  29. pmc IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy
    Charles Ferte
    INSERM U1030, Villejuif, France
    Mol Cancer Ther 12:1213-22. 2013
    ..In conclusion, adding R1507 to the current standard cisplatin-IR doublet reveals remarkable chemo- and radiosensitizing effects in selected SCLC models and warrants to be investigated in the clinical setting...
  30. doi request reprint The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines' in-vitro and in-vivo xenografts
    Mélanie Deberne
    INSERM U1030, Molecular Radiotherapy, Paris XI University, France
    Anticancer Drugs 24:599-608. 2013
    ..The current data support a synergistic antiproliferative action of the Cd-Cx combination on HPV-related cervical tumors...
  31. doi request reprint Combination of vascular disrupting agents and ionizing radiation
    Céline Clémenson
    INSERM U1030, Radiothérapie moléculaire, Universite Paris XI, LabEx LERMIT, Institut Gustave Roussy, 114 rue E Vaillant, 94805 Villejuif Cedex, France
    Crit Rev Oncol Hematol 86:143-60. 2013
    ..However, up to date, there is a lack of clinical trials evaluating such combinations, whereas it would be of great interest since radiotherapy is widely used as anticancer treatment...
  32. doi request reprint Understanding the functions of tumor stroma in resistance to ionizing radiation: emerging targets for pharmacological modulation
    Cyrus Chargari
    Radiation Oncology, Hôpital d Instruction des Armées du Val de Grâce, Paris, France
    Drug Resist Updat 16:10-21. 2013
    ..The increasing knowledge of the relationship between stroma and response to IR could help developing innovative strategies for potentially improve antitumor effect of RT...
  33. doi request reprint Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection
    Monica Mangoni
    Laboratoire UPRES EA 2710, Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 74:1242-50. 2009
    ....
  34. doi request reprint Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy
    Renaud Mazeron
    Radiation Oncology, Institut Gustave Roussy, Villejuif Cedex, France
    Cancer Treat Rev 37:476-86. 2011
    ..The objective of this article is to review the concept of targeted antiangiogenic agents and the early clinical results of their use in combination with radiation therapy...
  35. ncbi request reprint Chemoprevention of lung cancer
    Jean Charles Soria
    Departement of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 4:659-69. 2003
    ..Development of a risk model with intermediate endpoints is essential for future chemoprevention studies...
  36. doi request reprint Vemurafenib and radiosensitization
    Lise Boussemart
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    JAMA Dermatol 149:855-7. 2013
    ....
  37. doi request reprint The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models
    Céline Clémenson
    INSERM U1030, Radiothérapie moléculaire, Universite Paris XI, LabEx LERMIT, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France
    Invest New Drugs 31:273-84. 2013
    ..Our results provide a rationale for the use of ombrabulin in combination with two standard treatment regimens that are concurrent cisplatin-based chemoradiation and cetuximab plus ionizing radiation therapies, for the treatment of HNSCC...
  38. ncbi request reprint The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure
    Michel Ducreux
    Unité de Gastroentérologie, Departement de Medecine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Best Pract Res Clin Gastroenterol 21:997-1014. 2007
    ..For advanced disease, chemotherapy alone has given very disappointing results. A multidisciplinary approach combining biological assessment of targets with clinical trials to evaluate new targeted drugs should be considered...
  39. ncbi request reprint Endothelial-cell apoptosis and tumour response to radiotherapy
    Bassam Abdulkarim
    Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 5:9. 2004
  40. ncbi request reprint Gene expression profile in human late radiation enteritis obtained by high-density cDNA array hybridization
    Marie Catherine Vozenin-Brotons
    Laboratoire UPRES EA 27 10 Radiosensibilité des Tumeurs et Tissus Sains, Institut Gustave Roussy Institut de Radioprotection et de Sureté Nucléaire, Villejuif, France
    Radiat Res 161:299-311. 2004
    ..e. the mucosa, the mesenchyme, and blood vessels. Functional studies will be necessary to validate the present results...
  41. ncbi request reprint Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells
    Eric Deutsch
    Department of Clinical Biology, Institut Gustave Roussy, Villejuif, France
    Blood 101:4583-8. 2003
    ..These findings reveal a novel link between the oncoprotein BCR-ABL and the tumor-suppressor protein BRCA1...
  42. ncbi request reprint Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies
    Bassam Abdulkarim
    Laboratoire UPRES EA No 27 10 Radiosensibilité des tumeurs tissus sains, France
    Oncogene 22:2260-71. 2003
    ..These results provide the basis for a novel anticancer strategy to enhance the therapeutic ratio of IR in EBV-related cancers...
  43. ncbi request reprint New concepts for phase I trials: evaluating new drugs combined with radiation therapy
    Eric Deutsch
    Radiation Oncology Department, University of Pennsylvania, Philadelphia, USA
    Nat Clin Pract Oncol 2:456-65. 2005
    ..It will be necessary to rethink phase I strategies, toxicity endpoints, and trial designs and concepts in order to fully optimize these regimens...
  44. doi request reprint Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity
    Remko Prevo
    Radiobiology Research Institute, Oxford University, Oxford, United Kingdom
    Cancer Res 68:5915-23. 2008
    ..These results indicate that pharmacologic inhibitors with enhanced specificity for class I PI3K may be of benefit when combined with radiotherapy...
  45. ncbi request reprint Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo
    Laurence Maggiorella
    Laboratoire Radiosensibilité des Tumeurs et des Tissus Sains UPRES EA 27 10, 94805 Villejuif, Cedex, France
    Cancer Res 63:2513-7. 2003
    ..In conclusion, we found a novel effect on DNA repair of the CDK inhibitor roscovitine, which acts as a radiosensitizer in vitro and in vivo in breast cancer cells lacking a functional p53...
  46. pmc Influence of endothelial cells on vascular smooth muscle cells phenotype after irradiation: implication in radiation-induced vascular damages
    Fabien Milliat
    Laboratory of Radiopathology, Institute for Radiological Protection and Nuclear Safety IRSN, BP17, 92262 Fontenay aux Roses, France
    Am J Pathol 169:1484-95. 2006
    ..Moreover, we demonstrate in vitro that ECs influence these fundamental mechanisms involved in radiation-induced vascular damages...
  47. ncbi request reprint Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers
    Bassam Abdulkarim
    Laboratoire UPRES EA N degrees 27 10 Radiosensibilité Radiocarcinogénèse humaine and Unité METSI, Institut Gustave Roussy, 94805 Villejuif, France
    Oncogene 21:2334-46. 2002
    ..This study provides the basis for a new anticancer strategy to enhance the antitumor effect of ionizing radiation in HPV-related cancers, without increase deleterious effects...
  48. pmc Design and implementation of microarray gene expression markup language (MAGE-ML)
    Paul T Spellman
    Department of Cell and Molecular Biology, University of California at Berkeley, Berkeley, CA 94720 3206, USA
    Genome Biol 3:RESEARCH0046. 2002
    ..Only when data can be easily exchanged will the entire biological community be able to derive the full benefit from such microarray studies...
  49. ncbi request reprint Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell lines
    Keith A Cengel
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Cancer Biol Ther 5:1206-10. 2006
    ..Thus, radiosensitization of human cancer cells that express mutated K-RAS occurred under conditions where AZD3409 inihibits the activation of farneyslated H-RAS, but did not inhibit K-RAS activation...
  50. ncbi request reprint Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model
    Laurence Maggiorella
    Laboratoire UPRES EA No 27 10 Radiosensibilité des tumeurs et tissus sains, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Anticancer Res 25:4357-62. 2005
    ..These data suggested that Ritonavir could clinically improve the tumor response to radiation therapy, especially in head and neck carcinoma...
  51. pmc Essential role of plasminogen activator inhibitor type-1 in radiation enteropathy
    Fabien Milliat
    Laboratory of Radiopathology, Institute for Radiological Protection and Nuclear Safety, Fontenay aux Roses Unité Propre de Recherche et de l Enseignement Supérieur, Equipe d Accueil 2710, France
    Am J Pathol 172:691-701. 2008
    ..Together, these data demonstrate that PAI-1 plays a critical role in radiation-induced intestinal damage, suggesting that PAI-1 is an attractive target for preventing or reducing the side effects of radiation therapy...
  52. ncbi request reprint [Perspectives in biological modulation of radiotherapy]
    Eric Deutsch
    Laboratoire UPRES EA2710 radiosensibilité des tumeurs et tissus sains, Institut Gustave Roussy, 39 rue Camille Desmoulin, 94805 Villejuif, Unite 350 INSERM
    Bull Cancer 92:90-6. 2005
    ..These approaches attempt to widen the therapeutic ratio of radiation, i.e. to increase specifically tumor radiation response with little impact on normal tissue response...
  53. ncbi request reprint Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer
    Yungan Tao
    Institute Gustave Roussy and the Department of Radiation Oncology of Cancer Hospital, Fu Dan University, Shanghai, China
    Nat Clin Pract Oncol 4:591-602. 2007
    ..This Review highlights the most relevant studies in this exciting area of research, focusing in particular on the role of IGF1R in resistance to other receptor-targeted therapies for cancer...